Health & Fitness
Health and Fitness
Health and Fitness 
Mon, May 16, 2011
Columbia Laboratories Added to NASDAQ Biotechnology Index
LIVINGSTON, N.J.--([ BUSINESS WIRE ])--Columbia Laboratories, Inc. (Nasdaq: CBRX) today announced the Company will be added to the NASDAQ Biotechnology Index® (Nasdaq: NBI). The semi-annual re-ranking of the index will become effective when the market opens on Monday May 23, 2011.
The NASDAQ Biotechnology Index is designed to track the performance of a set of NASDAQ listed securities that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). The Index is re-ranked semi-annually in May and November, and serves as the basis for the iShares NASDAQ Biotechnology Index FundSM (IBB). For more information about the NASDAQ Biotechnology Index, including eligibility criteria, visit [ www.nasdaq.com ].
About Columbia Laboratories
Columbia Laboratories, Inc. is developing products that utilize its novel bioadhesive drug delivery technologies to optimize drug delivery in a controlled, sustained manner. The Company has developed and sold six products for the U.S. market including CRINONE® (progesterone gel) for which Columbia receives royalties on annual net sales from Watson Pharmaceuticals. CRINONE is commercialized outside the U.S. by Merck Serono. The Company submitted a New Drug Application (NDA) to the Food and Drug Administration for PROCHIEVE® (progesterone gel) for the reduction of risk of preterm birth in women with short uterine cervical length in the mid-trimester of pregnancy on April 26, 2011.
Columbia's press releases and other company information are available online at [ www.columbialabs.com ].
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: This communication contains forward-looking statements, which statements are indicated by the words amay,a awill,a aplans,a abelieves,a aexpects,a aintends,a aanticipates,a apotential,a ashould,a and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those projected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. Factors that might cause future results to differ include, but are not limited to, the following: the successful marketing of CRINONE® by Watson Pharmaceuticals, Inc., in the United States; the successful marketing of CRINONE by Merck Serono outside the United States; successful development of a next-generation vaginal progesterone product; acceptance for filing by the United States Food and Drug Administration (aFDAa) of the New Drug Application (aNDAa) for PROCHIEVE® in the preterm birth indication; the decision of the FDA on Columbia's request for Priority Review for this NDA; the outcome of further statistical analyses by the FDA of the clinical data generated during the PREGNANT Study; success in obtaining timely FDA approval of PROCHIEVE in the preterm birth indication; the ability of our third-party manufacturers to supply CRINONE and PROCHIEVE; the impact of competitive products and pricing; the timely and successful negotiation of partnerships or other transactions; the strength of the United States dollar relative to international currencies, particularly the euro; competitive economic and regulatory factors in the pharmaceutical and healthcare industry; general economic conditions; and other risks and uncertainties that may be detailed, from time-to-time, in Columbia's reports filed with the SEC. Columbia does not undertake any responsibility to revise or update any forward-looking statements contained herein.
CRINONE® and PROCHIEVE® are registered trademarks of Watson Pharmaceuticals, Inc.